SCHEMBL20164537

SCHEMBL20164537

CCCNc1nc(Cl)nc2c(NC[C@@H](C)O)nc(Cl)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 6/20 0.41
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
ESR1 P03372 1/20 0.33
PDE10A Q9Y233 1/20 0.33
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
NR1I2 O75469 1/20 0.33
AHR P35869 1/20 0.33
HDAC1 Q13547 3/20 0.33
HDAC2 Q92769 3/20 0.33
HDAC8 Q9BY41 2/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC10 Q969S8 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20164488 1.00 SLC29A1 (0.41) SLC29A1KMT2ASMN1; SMN2ESR1PDE10A
SCHEMBL20164505 1.00 SLC29A1 (0.41) SLC29A1KMT2ASMN1; SMN2ESR1PDE10A
SCHEMBL20164620 0.86 SLC29A1 (0.40) SLC29A1KMT2APDE10ANR1I2AHR
SCHEMBL16094375 0.85 SLC29A1 (0.47) SLC29A1KMT2APDE10ANR1I2AHR
SCHEMBL20164539 0.82 SLC29A1 (0.38) SLC29A1KMT2APDE10ANR1I2AHR
SCHEMBL20164658 0.82 SLC29A1 (0.39) SLC29A1KMT2APDE10ANR1I2AHR
SCHEMBL20164638 0.80 SLC29A1 (0.54) SLC29A1KMT2APDE10ANR1I2AHR
SCHEMBL20164624 0.80 SLC29A1 (0.44) SLC29A1CSNK2A2CSNK2BCSNK2A1
SCHEMBL20164310 0.80 SLC29A1 (0.44) SLC29A1CSNK2A2CSNK2BCSNK2A1
SCHEMBL20164496 0.80 SLC29A1 (0.44) SLC29A1CSNK2A2CSNK2BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 SLC29A1 4472/4885KMT2A 2456/4885SMN1; SMN2 463/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 SLC29A1 4518/4885KMT2A 2528/4885SMN1; SMN2 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.